Monopar Therapeutics Enters into License Agreement with Alexion, a Subsidiary of AstraZeneca, for Global Development and Commercialization of ALXN1840 in Wilson Disease

Gelonghui October 24 | Monopar Therapeutics, a drug developer, has signed an agreement with Alexion, a subsidiary of AstraZeneca, to take over the future global development and commercialization activities of an experimental drug for Wilson’s disease that is currently under testing by Alexion. Wilson’s disease is a rare genetic disorder. According to the terms of the deal, Monopar will make an upfront payment to Alexion in the form of cash plus equity.